This Article Full Text Full Text (PDF) Supplemental Data Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tsao, D. Articles by Lin, J. C. Search for Related Content PubMed PubMed Citation Articles by Tsao, D. Articles by Lin, J. C. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Hazardous Substances DB GLUCOSE LITHIUM CHLORIDE LITHIUM COMPOUNDS Medline Plus Health Information Obesity

TrkB Agonists Ameliorate Obesity and Associated Metabolic Conditions in Mice

Rinat Laboratories, Pfizer Inc., South San Francisco, California 94080

Address all correspondence and requests for reprints to: John C. Lin, Rinat Laboratories, Pfizer Inc., 230 East Grand Avenue, South San Francisco, California 94080. E-mail: john.lin{at}rinat.pfizer.com.

Mutations in the tyrosine kinase receptor trkB or in one of its natural ligands, brain-derived neurotrophic factor (BDNF), lead to severe hyperphagia and obesity in rodents and/or humans. Here, we show that peripheral administration of neurotrophin-4 (NT4), the second natural ligand for trkB, suppresses appetite and body weight in a dose-dependent manner in several murine models of obesity. NT4 treatment increased lipolysis, reduced body fat content and leptin, and elicited long-lasting amelioration of hypertriglyceridemia and hyperglycemia. After treatment termination, body weight gradually recovered to control levels in obese mice with functional leptin receptor. A single intrahypothalamic application of minute amounts of NT4 or an agonist trkB antibody also reduced food intake and body weight in mice. Taken together with the genetic evidence, our findings support the concept that trkB signaling, which originates in the hypothalamus, directly modulates appetite, metabolism, and taste preference downstream of the leptin and melanocortin 4 receptor. The trkB agonists mediate anorexic and weight-reducing effects independent of stress induction, visceral discomfort, or pain sensitization and thus emerge as a potential therapeutic for metabolic disorders.

This article has been cited by other articles:

				B. Bariohay, J. Roux, C. Tardivel, J. Trouslard, A. Jean, and B. Lebrun Brain-Derived Neurotrophic Factor/Tropomyosin-Related Kinase Receptor Type B Signaling Is a Downstream Effector of the Brainstem Melanocortin System in Food Intake Control Endocrinology, June 1, 2009; 150(6): 2646 - 2653. [Abstract] [Full Text] [PDF]